BCMA-directed biologics and cell therapies for multiple myeloma

•  Overview of clinical development of idecabtagene vicleucel (ide-cel), a BMCA directed CAR T cell therapy for multiple myeloma
• Introduction to next generation BCMA-directed CAR T cell therapies 
• Discussion of full BCMA campaign, including BCMA directed bispecific T cell engagers and antibody drug conjugates

Kristen Hege, Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers-Squibb